

**MEDICAID PHARMACY PRIOR AUTHORIZATION ADVISORY COMMITTEE**  
**Recommendations Summary**  
**November 9, 2011**

**In Attendance:**

	Committee Member	Yes or No
1	Rosanne Barber	Present until 1:30pm. Rosanne Barber was not present for the voting session
2	Catherine Decker PharmD	Yes
3	Bradley Fedderly M.D.	Yes
4	Lawrence Fleming M.D.	Yes
5	Al Liegel, RPh	Yes
6	Kevin Izard M.D.	Yes
7	Steve Maike RPh	Yes
8	Pat Towers	Yes
9	Alicia Walker PharmD	No
10	Michael Witkovsky M.D.	Present 10:30am until close of meeting
11	James Boblin M.D.	Present 12:45pm until close of meeting
12	Ward Brown, M.D.	NO
13	Ronald Diamond, M.D.	Present 1:20pm until close of meeting

**HEPATITIS C AGENTS**  
**ALZHEIMER'S AGENTS**  
**ANTICONVULSANTS**  
**ANTIDEPRESSANTS, OTHER**  
**ANTIDEPRESSANTS, SSRIs**  
**ANTIPARKINSON'S AGENTS**  
**ANTIPSYCHOTICS**  
**SEDATIVE HYPNOTICS**  
**STIMULANTS AND RELATED AGENTS**  
**ANALGESICS/ANESTHETICS, TOPICAL**  
**CYTOKINE AND CAM ANTAGONISTS**  
**FIBROMYALGIA AGENTS**  
**NSAIDS**  
**ANTIHIISTAMINES, MINIMALLY SEDATING**  
**BRONCHODILATORS, COPD**  
**BRONCHODILATORS, BETA AGONIST**  
**COUGH AND COLD, NARCOTIC**  
**EPINEPHRINE, SELF-INJECTED**  
**GLUCOCORTICOID, INHALED**  
**INTRANASAL RHINITIS AGENTS**  
**LEUKOTRIENE MODIFIERS**  
**OPHTHALMIC ANTIBIOTICS**  
**OPHTHALMIC ANTIINFLAMMATORIES**  
**OPHTHALMICS FOR ALLERGIC CONJUNCTIVITIS**  
**OPHTHALMICS, GLAUCOMA AGENTS**  
**OTIC ANTIBIOTICS**  
**IMMUNOMODULATORS, ATOPIC DERMATITIS**  
**STEROIDS, TOPICAL - LOW POTENCY**  
**STEROIDS, TOPICAL - MEDIUM POTENCY**  
**STEROIDS, TOPICAL - HIGH POTENCY**  
**STEROIDS, TOPICAL - VERY HIGH POTENCY**  
**ANTIHYPERURICEMICS, ORAL**  
**BILE SALTS**  
**OPHTHALMIC ANTIBIOTIC/STEROID COMBINATIONS**  
**OTIC ANTI-INFECTIVES & ANESTHETICS**

<b>HEPATITIS C AGENTS</b>						
<b>Brand Name</b>	<b>Current Market Share</b>	<b>Current PDL Status</b>	<b>PDL Recommendation</b>	<b>COMMITTEE RECOMMENDATIONS</b>	<b>STATE MODIFICATIONS</b>	<b>SECRETARY MODIFICATIONS</b>
RIBAVIRIN TABLET (ORAL)	73.9%	ON	<b>Yes-Generic</b>			
RIBAVIRIN CAPSULE (ORAL)	0.0%	ON	<b>Yes-Generic</b>			
RIBASPHERE 400 MG (ORAL)	0.0%	ON	<b>No</b>			
RIBASPHERE 600 MG (ORAL)	0.0%	ON	<b>No</b>			
RIBAPAK (ORAL)	0.0%	ON	<b>No</b>			
VICTRELIS (ORAL)	0.0%	NR	<b>Yes</b>			
INCIVEK (ORAL)	0.0%	NR	<b>Yes</b>			

- Discussion: None
- Lawrence Fleming made a motion to accept staff recommendations as presented.
  - Second – Bradley Fedderly
  - All members were in favor of this motion
  - Motion passes.

<b>ALZHEIMERS AGENTS</b>						
<b>Brand Name</b>	<b>Current Market Share</b>	<b>Current PDL Status</b>	<b>PDL Recommendation</b>	<b>COMMITTEE RECOMMENDATIONS</b>	<b>STATE MODIFICATIONS</b>	<b>SECRETARY MODIFICATIONS</b>
DONEPEZIL (ORAL)	51.5%	ON	<b>Yes-Generic</b>			
DONEPEZIL ODT (ORAL)	0.2%	ON	<b>Yes-Generic</b>			
EXELON CAPSULES (ORAL)	0.3%	NR	<b>Yes</b>			
EXELON (TRANSDERM.)	5.3%	ON	<b>Yes</b>			
NAMENDA TAB DS PK (ORAL)	0.2%	ON	<b>Yes</b>			
NAMENDA TABLET (ORAL)	35.8%	ON	<b>Yes</b>			
ARICEPT 23 MG (ORAL)	0.7%	OFF	<b>No</b>			
GALANTAMINE ER (ORAL)	2.0%	ON	<b>No-Generic</b>			
GALANTAMINE TABLET (ORAL)	1.9%	ON	<b>No-Generic</b>			
NAMENDA SOLUTION (ORAL)	0.1%	ON	<b>Yes</b>			
RAZADYNE SOLUTION (ORAL)	0.0%	OFF	<b>No</b>			
EXELON SOLUTION (ORAL)	0.0%	OFF	<b>No</b>			
GALANTAMINE	0.0%	ON	<b>No-Generic</b>			

<b>ALZHEIMERS AGENTS</b>						
<b>Brand Name</b>	<b>Current Market Share</b>	<b>Current PDL Status</b>	<b>PDL Recommendation</b>	<b>COMMITTEE RECOMMENDATIONS</b>	<b>STATE MODIFICATIONS</b>	<b>SECRETARY MODIFICATIONS</b>
SOLUTION (ORAL)						
RIVASTIGMINE CAPSULES (ORAL)	2.1%	ON	No-Generic			

- Discussion: None
- James Boblin made a motion to accept staff recommendations as presented.
  - Second – Al Liegel
  - All members were in favor of this motion
  - Motion passes.

<b>ANTICONVULSANTS</b>						
<b>Brand Name</b>	<b>Current Market Share</b>	<b>Current PDL Status</b>	<b>PDL Recommendation</b>	<b>COMMITTEE RECOMMENDATIONS</b>	<b>STATE MODIFICATIONS</b>	<b>SECRETARY MODIFICATIONS</b>
CLONAZEPAM (ORAL)	29.8%	ON	Yes-Generic			
PHENOBARBITAL TABLET (ORAL)	2.2%	ON	Yes-Generic			
CARBAMAZEPINE TABLET (ORAL)	1.8%	ON	Yes-Generic			
TOPIRAMATE TABLETS (ORAL)	7.5%	ON	Yes-Generic			
LAMOTRIGINE (ORAL)	11.9%	ON	Yes-Generic			
TEGRETOL XR (ORAL)	0.2%	NR	Yes			
CARBAMAZEPINE TAB CHEW (ORAL)	0.6%	ON	Yes-Generic			
PRIMIDONE (ORAL)	0.8%	ON	Yes-Generic			
PHENOBARBITAL ELIXIR (ORAL)	0.5%	ON	Yes-Generic			
GABAPENTIN CAPSULE (ORAL)	14.8%	ON	Yes-Generic			
DIVALPROEX TABLET (ORAL)	3.5%	ON	Yes-Generic			
VALPROATE SYRUP (ORAL)	0.7%	ON	Yes-Generic			
LAMOTRIGINE TAB DS PK (ORAL)	0.0%	ON	Yes-Generic			
MEPHOBARBITAL (ORAL)	0.0%	ON	Yes-Generic			
CELONTIN (ORAL)	0.0%	ON	Yes			
ZONISAMIDE (ORAL)	1.0%	ON	Yes-Generic			
PHENYTOIN (ORAL)	1.3%	ON	Yes-Generic			
VALPROIC ACID (ORAL)	0.1%	ON	Yes-Generic			
LEVETIRACETAM TABLETS (ORAL)	3.8%	ON	Yes-Generic			
PHENYTOIN SUSPENSION (ORAL)	0.1%	ON	Yes-Generic			

<b>ANTICONVULSANTS</b>						
<b>Brand Name</b>	<b>Current Market Share</b>	<b>Current PDL Status</b>	<b>PDL Recommendation</b>	<b>COMMITTEE RECOMMENDATIONS</b>	<b>STATE MODIFICATIONS</b>	<b>SECRETARY MODIFICATIONS</b>
ETHOSUXIMIDE SYRUP (ORAL)	0.1%	ON	Yes-Generic			
GABAPENTIN TABLET (ORAL)	4.8%	ON	Yes-Generic			
CARBATROL (ORAL)	0.9%	ON	Yes			
DEPAKOTE SPRINKLE (ORAL)	0.2%	NR	Yes			
OXCARBAZEPINE TABLETS (ORAL)	1.9%	ON	Yes-Generic			
DIVALPROEX ER (ORAL)	5.0%	ON	Yes-Generic			
LEVETIRACETAM SOLUTION (ORAL)	1.2%	ON	Yes-Generic			
CLONAZEPAM ODT (ORAL)	0.5%	ON	No-Generic			
GABITRIL (ORAL)	0.1%	ON	Yes			
PEGANONE (ORAL)	0.0%	ON	Yes			
CARBAMAZEPINE SUSPENSION (ORAL)	0.2%	ON	Yes-Generic			
PHENYTEK (ORAL)	0.0%	OFF	No			
DILANTIN INFATAB (ORAL)	0.2%	ON	Yes			
FELBATOL SUSPENSION (ORAL)	0.2%	ON	Yes			
EQUETRO (ORAL)	0.0%	ON	No			
ETHOSUXIMIDE CAPSULE (ORAL)	0.1%	ON	Yes-Generic			
FELBATOL TABLET (ORAL)	0.3%	ON	Yes			
CARBAMAZEPINE XR (ORAL)	0.2%	OFF	No-Generic			
CARBAMAZEPINE ER (GENERIC CARBATROL) (ORAL)	0.0%	OFF	No-Generic			
DIVALPROEX SPRINKLE (ORAL)	1.1%	ON	No-Generic			
GABAPENTIN SOLUTION (ORAL)	0.0%	ON	Yes-Generic			
STAVZOR (ORAL)	0.0%	OFF	No			
GRALISE (ORAL)	0.0%	OFF	No			
LAMICTAL ODT DS PK (ORAL)	0.0%	OFF	No			
OXCARBAZEPINE SUSPENSION (ORAL)	0.2%	ON	Yes-Generic			
DIASTAT (RECTAL)	0.5%	ON	Yes			
KEPPRA XR (ORAL)	0.3%	ON	Yes			
TOPIRAMATE SPRINKLE (ORAL)	0.2%	ON	Yes-Generic			
LAMICTAL ODT (ORAL)	0.2%	OFF	No			

ANTICONVULSANTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
VIMPAT (ORAL)	0.4%	OFF	No			
LAMICTAL XR DS PK (ORAL)	0.0%	OFF	No			
DIAZEPAM (RECTAL)	0.0%	OFF	No-Generic			
BANZEL SUSPENSION (ORAL)	0.0%	OFF	No			
LEVETIRACETAM ER (ORAL)	0.0%	OFF	No-Generic			
BANZEL TABLET (ORAL)	0.2%	OFF	No			
LAMICTAL XR (ORAL)	0.2%	OFF	No			
FELBAMATE TABLET (ORAL)	0.0%	OFF	No			
SABRIL TABLET (ORAL)	0.0%	OFF	No			
SABRIL POWDER PACK (ORAL)	0.0%	OFF	No			

- Discussion: None
- Kevin Izard made a motion to accept staff recommendations as presented.
  - Second – Ronald Diamond
  - All members were in favor of this motion
  - Motion passes.

ANTIDEPRESSANTS, OTHER						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
WELLBUTRIN XL (ORAL)	0.1%	NR	Yes			
TRAZODONE (ORAL)	29.1%	ON	Yes-Generic			
MIRTAZAPINE (ORAL)	12.3%	ON	Yes-Generic			
EFFEXOR XR (ORAL)	1.6%	NR	Yes			
MARPLAN (ORAL)	0.0%	ON	Yes			
BUPROPION (ORAL)	2.0%	ON	Yes-Generic			
VENLAFAXINE ER CAPSULES (ORAL)	20.5%	ON	No-Generic			
VENLAFAXINE (ORAL)	3.6%	ON	Yes-Generic			
BUPROPION SR (ORAL)	15.1%	ON	Yes-Generic			
BUPROPION XL (ORAL)	13.5%	ON	No-Generic			
MIRTAZAPINE ODT (ORAL)	0.3%	ON	Yes-Generic			
VENLAFAXINE ER TABLETS (UPSTATE) (ORAL)	0.1%	OFF	No-Generic			

**ANTIDEPRESSANTS, OTHER**

Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
NARDIL (ORAL)	0.0%	ON	Yes			
NEFAZODONE (ORAL)	0.2%	OFF	No-Generic			
VIIBRYD (ORAL)	0.0%	NR	No			
TRANLYCYPROMINE SULFATE (ORAL)	0.0%	ON	Yes-Generic			
PRISTIQ (ORAL)	1.5%	OFF	No			
PHENELZINE (ORAL)	0.0%	OFF	No-Generic			
OLEPTRO ER (ORAL)	0.0%	NR	No			
VENLAFAXINE ER TABLETS (SCHWARZ) (ORAL)	0.1%	OFF	No-Generic			
VENLAFAXINE ER TABLETS (GENERIC) (ORAL)	0.0%	OFF	No-Generic			
APLENZIN (ORAL)	0.0%	OFF	No			
EMSAM (TRANSDERMAL)	0.0%	OFF	No			

- Discussion: None
- Bradley Fedderly made a motion to accept staff recommendations as presented.
  - Second – Pat Towers
  - All members were in favor of this motion
  - Motion passes.

**ANTIDEPRESSANTS, SSRIs**

Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
FLUOXETINE 20 MG TABLET (ORAL)	1.8%	ON	Yes-Generic			
CITALOPRAM TABLET (ORAL)	29.7%	ON	Yes-Generic			
FLUOXETINE 10 MG TABLET (ORAL)	1.6%	ON	Yes-Generic			
SERTRALINE TABLET (ORAL)	28.0%	ON	Yes-Generic			
FLUOXETINE CAPSULE (ORAL)	21.4%	ON	Yes-Generic			
PAROXETINE TABLET (ORAL)	10.1%	ON	Yes-Generic			
FLUOXETINE SOLUTION (ORAL)	0.3%	ON	Yes-Generic			
PAXIL SUSPENSION (ORAL)	0.0%	ON	Yes			
FLUVOXAMINE (ORAL)	0.6%	ON	Yes-Generic			
CITALOPRAM SOLUTION (ORAL)	0.1%	ON	Yes-Generic			
LEXAPRO TABLET (ORAL)	5.9%	OFF	No			
PEXEVA (ORAL)	0.0%	OFF	No			
SERTRALINE CONC (ORAL)	0.1%	ON	Yes-Generic			
LEXAPRO SOLUTION (ORAL)	0.0%	OFF	No			
PAROXETINE CR (ORAL)	0.2%	OFF	No-Generic			

<b>ANTIDEPRESSANTS, SSRI's</b>						
<b>Brand Name</b>	<b>Current Market Share</b>	<b>Current PDL Status</b>	<b>PDL Recommendation</b>	<b>COMMITTEE RECOMMENDATIONS</b>	<b>STATE MODIFICATIONS</b>	<b>SECRETARY MODIFICATIONS</b>
FLUOXETINE CAPSULE DR (ORAL)	0.0%	OFF	<b>No-Generic</b>			
LUVOX CR (ORAL)	0.0%	OFF	<b>No</b>			

- Discussion: None
- Ronald Diamond made a motion to accept staff recommendations as presented.
  - Second – Steve Maike
  - All members were in favor of this motion
  - Motion passes.

<b>ANTIPARKINSONS AGENTS</b>						
<b>Brand Name</b>	<b>Current Market Share</b>	<b>Current PDL Status</b>	<b>PDL Recommendation</b>	<b>COMMITTEE RECOMMENDATIONS</b>	<b>STATE MODIFICATIONS</b>	<b>SECRETARY MODIFICATIONS</b>
BENZTROPINE (ORAL)	32.3%	ON	<b>Yes-Generic</b>			
TRIHENYPHENIDYL TABLET (ORAL)	5.3%	ON	<b>Yes-Generic</b>			
TASMAR (ORAL)	0.1%	OFF	<b>No</b>			
PRAMIPEXOLE (ORAL)	7.5%	ON	<b>Yes-Generic</b>			
CARBIDOPA / LEVODOPA (ORAL)	16.7%	ON	<b>Yes-Generic</b>			
ROPINIROLE (ORAL)	30.4%	ON	<b>Yes-Generic</b>			
CARBIDOPA / LEVODOPA ER (ORAL)	3.7%	ON	<b>Yes-Generic</b>			
TRIHENYPHENIDYL ELIXIR (ORAL)	0.4%	ON	<b>Yes-Generic</b>			
SELEGILINE TABLET (ORAL)	0.1%	ON	<b>Yes-Generic</b>			
ZELAPAR (ORAL)	0.0%	OFF	<b>No</b>			
SELEGILINE CAPSULE (ORAL)	0.3%	ON	<b>Yes-Generic</b>			
BROMOCRIPTINE (ORAL)	1.4%	ON	<b>Yes-Generic</b>			
STALEVO (ORAL)	0.9%	ON	<b>Yes</b>			
CARBIDOPA / LEVODOPA ODT (ORAL)	0.1%	ON	<b>Yes-Generic</b>			
COMTAN (ORAL)	0.2%	OFF	<b>No</b>			
AZILECT (ORAL)	0.3%	OFF	<b>No</b>			
MIRAPEX ER (ORAL)	0.0%	OFF	<b>No</b>			
REQUIP XL (ORAL)	0.4%	OFF	<b>No</b>			

- Discussion: None
- James Boblin made a motion to accept staff recommendations as presented.
  - Second – Al Liegel
  - All members were in favor of this motion
  - Motion passes.



<b>ANTIPSYCHOTICS</b>						
<b>Brand Name</b>	<b>Current Market Share</b>	<b>Current PDL Status</b>	<b>PDL Recommendation</b>	<b>COMMITTEE RECOMMENDATIONS</b>	<b>STATE MODIFICATIONS</b>	<b>SECRETARY MODIFICATIONS</b>
FLUPHENAZINE TABLET (ORAL)	0.9%	ON	Yes-Generic			
HALOPERIDOL LACTATE CONC (ORAL)	0.1%	ON	Yes-Generic			
THIOTHIXENE (ORAL)	0.5%	ON	Yes-Generic			
RISPERIDONE TABLET (ORAL)	25.2%	ON	Yes-Generic			
CHLORPROMAZINE (ORAL)	0.8%	ON	Yes-Generic			
HALOPERIDOL (ORAL)	3.2%	ON	Yes-Generic			
ORAP (ORAL)	0.1%	ON	Yes			
TRIFLUOPERAZINE (ORAL)	0.2%	ON	Yes-Generic			
MOBAN (ORAL)	0.0%	ON	Yes			
AMITRIPTYLINE / PERPHENAZINE (ORAL)	0.1%	ON	Yes-Generic			
PERPHENAZINE (ORAL)	0.4%	ON	Yes-Generic			
FANAPT TAB DS PK (ORAL)	0.0%	OFF	No			
RISPERIDONE SOLUTION (ORAL)	0.9%	ON	Yes-Generic			
FANAPT TABLET (ORAL)	0.2%	OFF	Yes	OFF		
RISPERIDONE ODT (ORAL)	0.8%	ON	Yes-Generic			
SEROQUEL (ORAL)	28.8%	ON	Yes			
SAPHRIS (SUBLINGUAL)	0.2%	OFF	No			
GEODON (ORAL)	9.6%	ON	Yes			
SEROQUEL XR (ORAL)	1.4%	OFF	No			
CLOZAPINE (ORAL)	2.7%	ON	Yes-Generic			
FLUPHENAZINE ELIXIR/SOLN (ORAL)	0.0%	ON	Yes-Generic			
SYMBYAX (ORAL)	0.1%	OFF	No			
ABILIFY TABLET (ORAL)	15.6%	OFF	No			
FAZACLO (ORAL)	0.3%	OFF	No			
INVEGA (ORAL)	1.1%	OFF	No			
ZYPREXA (ORAL)	5.9%	OFF	No			
LATUDA (ORAL)	0.0%	OFF	No			
ABILIFY DISCMELT (ORAL)	0.0%	OFF	No			
ZYPREXA ZYDIS (ORAL)	0.7%	OFF	No			
ABILIFY SOLUTION (ORAL)	0.2%	OFF	No			

- Discussion:
- James Boblin inquired about what the MHDA committee recommendations were for this class.

MHDA response:

- Some MHDA indicated Fanapt was not their first choice for addition as a preferred brand drug in this class. Fanapt requires dose titration and there is the potential of orthostatic hypotension
- Some MHDA indicated their first choice for additional preferred brand drugs would be Saphris and/or Latuda instead of Fanapt

- Some MHDA were concerned that new drugs should not be preferred when little clinical information is available
  - Some MHDA suggested that all three medications (Fanapt, Saphris, Latuda) remain non-preferred
  - MHDA were concerned about the increased healthcare costs due to metabolic side effects with some atypical antipsychotics. It was noted that many patients are started on Zyprexa in an acute care setting. However, due to potential metabolic side effects, it is not always a desired long term therapy. The MHDA were split whether Zyprexa (olanzapine), once it becomes generic, should remain non-preferred or become a preferred drug
  - Some MHDA supported the prior authorization requirement on Abilify and Seroquel XR. It was suggested that without the prior authorization requirement, consumer pressure on providers would increase prescribing of these medications
- Ronald Diamond also responded that there were concerns raised about whether Fanapt should be preferred or not. The only way it should be preferred is if it is at par with the generic prices.
  - Pat Towers made a motion to make Fanapt non-preferred and accept the remainder of staff recommendations as presented.
    - Second – Michael Witkovsky
    - All members were in favor of this motion
    - Motion passes

<b>SEDATIVE HYPNOTICS</b>						
<b>Brand Name</b>	<b>Current Market Share</b>	<b>Current PDL Status</b>	<b>PDL Recommendation</b>	<b>COMMITTEE RECOMMENDATIONS</b>	<b>STATE MODIFICATIONS</b>	<b>SECRETARY MODIFICATIONS</b>
ZOLPIDEM TARTRATE (ORAL)	68.1%	ON	<b>Yes-Generic</b>			
TEMAZEPAM (ORAL)	21.4%	ON	<b>Yes-Generic</b>			
FLURAZEPAM (ORAL)	0.3%	OFF	<b>No-Generic</b>			
TRIAZOLAM (ORAL)	0.6%	OFF	<b>No-Generic</b>			
CHLORAL HYDRATE SYRUP (ORAL)	0.2%	ON	<b>Yes-Generic</b>			
ZALEPLON (ORAL)	1.2%	ON	<b>Yes-Generic</b>			
ESTAZOLAM (ORAL)	0.6%	ON	<b>Yes-Generic</b>			
DORAL (ORAL)	0.0%	OFF	<b>No</b>			
LUNESTA (ORAL)	3.2%	OFF	<b>No</b>			
ZOLPIMIST (ORAL)	0.0%	OFF	<b>No</b>			
SOMNOTE (ORAL)	0.1%	ON	<b>No</b>			
ROZEREM (ORAL)	2.1%	ON	<b>Yes</b>			
EDLUAR (SUBLINGUAL)	0.0%	OFF	<b>No</b>			
SILENOR (ORAL)	0.1%	NR	<b>No</b>			
ZOLPIDEM ER (ORAL)	2.3%	OFF	<b>No-Generic</b>			
TEMAZEPAM 7.5 MG (ORAL)	0.0%	OFF	<b>No-Generic</b>			
TEMAZEPAM 22.5 MG (ORAL)	0.0%	OFF	<b>No-Generic</b>			

- Discussion: None
- Brad Fedderly made a motion to accept staff recommendations as presented.
  - Second – Michael Witkovsky
  - All members were in favor of this motion
  - Motion passes.

<b>STIMULANTS AND RELATED AGENTS</b>						
<b>Brand Name</b>	<b>Current Market Share</b>	<b>Current PDL Status</b>	<b>PDL Recommendation</b>	<b>COMMITTEE RECOMMENDATIONS</b>	<b>STATE MODIFICATIONS</b>	<b>SECRETARY MODIFICATIONS</b>
METHYLPHENIDATE (ORAL)	7.8%	ON	<b>Yes-Generic</b>			
METHYLIN SOLUTION (ORAL)	0.1%	OFF	<b>No</b>			
AMPHETAMINE SALT COMBO (ORAL)	16.8%	ON	<b>Yes-Generic</b>			
METHYLIN CHEWABLE TABLETS (ORAL)	0.1%	OFF	<b>Yes</b>			
DEXTROAMPHETAMINE TABLET (ORAL)	1.0%	ON	<b>Yes-Generic</b>			
METHYLPHENIDATE ER (ORAL)	2.2%	ON	<b>Yes-Generic</b>			
METADATE CD (ORAL)	2.4%	ON	<b>Yes</b>			
VYVANSE (ORAL)	13.8%	ON	<b>Yes</b>			
FOCALIN XR (ORAL)	4.7%	ON	<b>Yes</b>			
DEXMETHYLPHENIDATE (ORAL)	0.9%	ON	<b>Yes-Generic</b>			
CONCERTA (ORAL)	15.5%	ON	<b>Yes</b>			
ADDERALL (ORAL)	0.0%	NR	<b>Yes</b>			
RITALIN LA (ORAL)	0.6%	OFF	<b>No</b>			
ADDERALL XR (ORAL)	8.3%	ON	<b>Yes</b>			
DAYTRANA (TRANSDERMAL)	1.0%	ON	<b>Yes</b>			
STRATTERA (ORAL)	3.6%	OFF	<b>No</b>			
KAPVAY (ORAL)	0.0%	OFF	<b>No</b>			
PROVIGIL (ORAL)	0.3%	OFF	<b>No</b>			
INTUNIV (ORAL)	1.6%	OFF	<b>No</b>			
DESOXYN (ORAL)	0.0%	OFF	<b>No</b>			
METHYLPHENIDATE ER (CONCERTA) (ORAL)	0.0%	OFF	<b>No-Generic</b>			
DEXTROAMPHETAMINE CAPSULE ER (ORAL)	1.3%	ON	<b>Yes-Generic</b>			
AMPHETAMINE SALT COMBO ER (TEVA) (ORAL)	2.7%	ON	<b>No-Generic</b>			
AMPHETAMINE SALT COMBO ER (GLOBAL) (ORAL)	15.2%	ON	<b>No-Generic</b>			
METHYLPHENIDATE SOLUTION (ORAL)	0.0%	OFF	<b>No-Generic</b>			
PROCENTRA (ORAL)	0.0%	OFF	<b>No</b>			
NUVIGIL (ORAL)	0.0%	OFF	<b>No</b>			
METHAMPHETAMINE (ORAL)	0.0%	OFF	<b>No-Generic</b>			

- Discussion: None
- Michael Witkovsky made a motion to accept staff recommendations as presented.
  - Second – Lawrence Fleming
  - All members were in favor of this motion
  - Motion passes.

<b>ANALGESICS-ANESTHETICS, TOPICAL</b>						
<b>Brand Name</b>	<b>Current Market Share</b>	<b>Current PDL Status</b>	<b>PDL Recommendation</b>	<b>COMMITTEE RECOMMENDATIONS</b>	<b>STATE MODIFICATIONS</b>	<b>SECRETARY MODIFICATIONS</b>
CAPSAICIN OTC (TOPICAL)	1.4%	ON	<b>Yes-Generic</b>			
VOLTAREN (TOPICAL)	26.8%	ON	<b>Yes</b>			
PENNSAID (TOPICAL)	0.1%	OFF	<b>No</b>			
LIDODERM (TOPICAL)	70.1%	ON	<b>No</b>			
FLECTOR (TOPICAL)	1.6%	OFF	<b>No</b>			

- Discussion: None
- Pat Towers made a motion to accept staff recommendations as presented.
  - Second – Bradley Fedderly
  - All members were in favor of this motion
  - Motion passes.

<b>CYTOKINE AND CAM ANTAGONISTS</b>						
<b>Brand Name</b>	<b>Current Market Share</b>	<b>Current PDL Status</b>	<b>PDL Recommendation</b>	<b>COMMITTEE RECOMMENDATIONS</b>	<b>STATE MODIFICATIONS</b>	<b>SECRETARY MODIFICATIONS</b>
ENBREL KIT (INJECTION)	2.5%	ON	<b>Yes</b>			
KINERET (INJECTION)	0.6%	OFF	<b>No</b>			
CIMZIA KIT (INJECTION)	1.3%	ON	<b>Yes</b>			
ENBREL DISP SYRINGE (INJECTION)	12.9%	ON	<b>Yes</b>			
ENBREL PEN (INJECTION)	21.2%	ON	<b>Yes</b>			
HUMIRA PEN IJ KIT (INJECTION)	41.9%	ON	<b>Yes</b>			
CIMZIA SYRINGE KIT (INJECTION)	4.4%	ON	<b>Yes</b>			
HUMIRA KIT (INJECTION)	13.8%	ON	<b>Yes</b>			
SIMPONI PEN INJECTER (INJECTION)	0.7%	OFF	<b>No</b>			
SIMPONI DISP SYRINGE (INJECTION)	0.6%	OFF	<b>No</b>			
ORENCIA (SUB-Q)	0.0%	NR	<b>No</b>			

- Discussion: None
- Kevin Izard made a motion to accept staff recommendations as presented.
  - Second – Al Liegel
  - All members were in favor of this motion
  - Motion passes.

<b>FIBROMYALGIA</b>						
<b>Brand Name</b>	<b>Current Market Share</b>	<b>Current PDL Status</b>	<b>PDL Recommendation</b>	<b>COMMITTEE RECOMMENDATIONS</b>	<b>STATE MODIFICATIONS</b>	<b>SECRETARY MODIFICATIONS</b>
SAVELLA DS PK (ORAL)	0.7%	ON	<b>Yes</b>			
CYMBALTA (ORAL)	38.4%	OFF	<b>No</b>			
SAVELLA (ORAL)	7.5%	ON	<b>Yes</b>			
LYRICA (ORAL)	53.5%	ON	<b>Yes</b>			

- Discussion: None
- Bradley Fedderly made a motion to accept staff recommendations as presented.
  - Second – James Boblin
  - All members were in favor of this motion
  - Motion passes.

<b>NSAIDS</b>						
<b>Brand Name</b>	<b>Current Market Share</b>	<b>Current PDL Status</b>	<b>PDL Recommendation</b>	<b>COMMITTEE RECOMMENDATIONS</b>	<b>STATE MODIFICATIONS</b>	<b>SECRETARY MODIFICATIONS</b>
ADVIL OTC (ORAL)	0.0%	ON	<b>Yes</b>			
DICLOFENAC POTASSIUM (ORAL)	0.6%	ON	<b>Yes-Generic</b>			
MELOXICAM TABLET (ORAL)	8.9%	ON	<b>Yes-Generic</b>			
IBUPROFEN TABLET OTC (ORAL)	1.1%	ON	<b>Yes-Generic</b>			
IBUPROFEN TABLET (ORAL)	35.2%	ON	<b>Yes-Generic</b>			
NAPROXEN TABLET (ORAL)	17.6%	ON	<b>Yes-Generic</b>			
PIROXICAM (ORAL)	1.2%	ON	<b>Yes-Generic</b>			
NAPROXEN SODIUM OTC (ORAL)	0.2%	ON	<b>Yes-Generic</b>			
IBUPROFEN SUSPENSION OTC (ORAL)	1.2%	ON	<b>Yes-Generic</b>			
KETOROLAC (ORAL)	1.8%	ON	<b>Yes-Generic</b>			
IBUPROFEN DROPS SUSPENSION OTC (ORAL)	0.2%	ON	<b>Yes-Generic</b>			
IBUPROFEN	10.5%	ON	<b>Yes-Generic</b>			

<b>NSAIDS</b>						
<b>Brand Name</b>	<b>Current Market Share</b>	<b>Current PDL Status</b>	<b>PDL Recommendation</b>	<b>COMMITTEE RECOMMENDATIONS</b>	<b>STATE MODIFICATIONS</b>	<b>SECRETARY MODIFICATIONS</b>
SUSPENSION (ORAL)						
IBUPROFEN TAB CHEW OTC (ORAL)	0.0%	ON	<b>Yes-Generic</b>			
IBUPROFEN CAPSULE OTC (ORAL)	0.0%	ON	<b>Yes-Generic</b>			
NAPROXEN SODIUM (ORAL)	1.6%	ON	<b>Yes-Generic</b>			
FLURBIPROFEN (ORAL)	0.1%	ON	<b>Yes-Generic</b>			
INDOMETHACIN CAPSULE (ORAL)	2.3%	ON	<b>Yes-Generic</b>			
OXAPROZIN (ORAL)	0.0%	OFF	<b>Yes-Generic</b>			
INDOCIN SUSPENSION (ORAL)	0.0%	OFF	<b>No</b>			
SULINDAC (ORAL)	0.0%	OFF	<b>Yes-Generic</b>			
KETOPROFEN (ORAL)	0.5%	ON	<b>Yes-Generic</b>			
PONSTEL (ORAL)	0.0%	OFF	<b>No</b>			
NAPROXEN EC (ORAL)	0.9%	ON	<b>Yes-Generic</b>			
DICLOFENAC SR (ORAL)	0.5%	ON	<b>Yes-Generic</b>			
ETODOLAC (ORAL)	0.1%	OFF	<b>Yes-Generic</b>			
VIMOVO (ORAL)	0.0%	NR	<b>No</b>			
DICLOFENAC SODIUM (ORAL)	7.9%	ON	<b>Yes-Generic</b>			
NAPROXEN SUSPENSION (ORAL)	0.2%	ON	<b>Yes-Generic</b>			
NABUMETONE (ORAL)	4.0%	ON	<b>No-Generic</b>			
MELOXICAM SUSPENSION (ORAL)	0.0%	ON	<b>No-Generic</b>			
FENOPROFEN (ORAL)	0.0%	OFF	<b>No-Generic</b>			
ETODOLAC TAB SR (ORAL)	0.0%	OFF	<b>No-Generic</b>			
ARTHROTEC (ORAL)	0.1%	OFF	<b>No</b>			
CELEBREX (ORAL)	2.9%	OFF	<b>No</b>			
DIFLUNISAL (ORAL)	0.1%	OFF	<b>No-Generic</b>			
MECLOFENAMATE (ORAL)	0.0%	ON	<b>No-Generic</b>			

<b>NSAIDS</b>						
<b>Brand Name</b>	<b>Current Market Share</b>	<b>Current PDL Status</b>	<b>PDL Recommendation</b>	<b>COMMITTEE RECOMMENDATIONS</b>	<b>STATE MODIFICATIONS</b>	<b>SECRETARY MODIFICATIONS</b>
KETOPROFEN ER (ORAL)	0.0%	ON	<b>No-Generic</b>			
INDOMETHACIN CAPSULE ER (ORAL)	0.4%	ON	<b>No-Generic</b>			
ZIPSOR (ORAL)	0.0%	OFF	<b>No</b>			
SPRIX (NASAL)	0.0%	OFF	<b>No</b>			
TOLMETIN SODIUM TABLET (ORAL)	0.0%	OFF	<b>No-Generic</b>			
TOLMETIN SODIUM CAPSULE (ORAL)	0.0%	OFF	<b>No-Generic</b>			
MEFENAMIC ACID (ORAL)	0.0%	OFF	<b>No-Generic</b>			

- Discussion: None
- Lawrence Fleming made a motion to accept staff recommendations as presented.
  - Second – Steve Maike
  - All members were in favor of this motion
  - Motion passes.

<b>ANTIHISTAMINES, MINIMALLY SEDATING</b>						
<b>Brand Name</b>	<b>Current Market Share</b>	<b>Current PDL Status</b>	<b>PDL Recommendation</b>	<b>COMMITTEE RECOMMENDATIONS</b>	<b>STATE MODIFICATIONS</b>	<b>SECRETARY MODIFICATIONS</b>
CETIRIZINE SOLUTION (ORAL)	5.9%	ON	<b>Yes-Generic</b>			
CETIRIZINE SOLUTION OTC (ORAL)	9.9%	ON	<b>Yes-Generic</b>			
CETIRIZINE TABLETS OTC (ORAL)	61.1%	ON	<b>Yes-Generic</b>			
SEMPREX-D (ORAL)	0.0%	OFF	<b>No</b>			
LORATADINE-D OTC (ORAL)	8.5%	ON	<b>Yes-Generic</b>			
CLARINEX SYRUP (ORAL)	0.1%	OFF	<b>No</b>			
XYZAL SOLUTION (ORAL)	0.2%	OFF	<b>No</b>			
CLARINEX TABLET (ORAL)	0.7%	OFF	<b>No</b>			
CLARINEX ODT (ORAL)	0.0%	OFF	<b>No</b>			
CETIRIZINE-D OTC (ORAL)	3.5%	ON	<b>Yes-Generic</b>			
CLARINEX-D 24 HOUR (ORAL)	0.1%	OFF	<b>No</b>			
CLARINEX-D 12 HOUR (ORAL)	0.0%	OFF	<b>No</b>			

**ANTI-HISTAMINES, MINIMALLY SEDATING**

Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
LEVOCETIRIZINE (ORAL)	0.5%	OFF	No-Generic			

- Discussion: None
- Al Liegel made a motion to accept staff recommendations as presented.
  - Second – Kevin Izard
  - All members were in favor of this motion
  - Motion passes.

**COPD AGENTS**

Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
IPRATROPIUM NEBULIZER (INHALATION)	8.4%	ON	Yes-Generic			
DUONEB (INHALATION)	0.1%	NR	No			
COMBIVENT (INHALATION)	36.9%	ON	Yes			
IPRATROPIUM / ALBUTEROL (INHALATION)	10.8%	ON	Yes-Generic			
ATROVENT HFA (INHALATION)	4.4%	ON	Yes			
SPIRIVA (INHALATION)	39.5%	ON	Yes			
DALIRESP (ORAL)	0.0%	NR	No			

- Discussion:
- Kevin Izard stated that he was “up in the air” about Daliresp being non-preferred considering it may be effective in decreasing hospitalizations which would ultimately save money and improve quality. He would like the committee to take a closer look at this drug when more data is available.
- Bradley Fedderly recommended that the committee review Daliresp again at the next meeting in May.
- Lawrence Fleming stated that even if it is non-preferred, it is still available via STAT-PA.
- Catherine Decker stated that if the member is in the hospital, there should be plenty of time to get a PA done before the member is discharged. Catherine was in support of Daliresp remaining non-preferred.
- James Boblin asked if we can track COPD admissions. He stated that medications that can keep members out of the ER or hospital are much less expensive than the hospital.
- Ron Diamond stated that the committee should keep in mind that it is still available, but we are deciding if it should require a PA.
- Brett Davis responded that DHS would try to review COPD admission data for further information.
- Pat Towers made a motion to accept staff recommendations as presented.
  - Second – Ronald Diamond
  - All members were in favor of this motion
  - Motion passes

**BRONCHODILATORS, BETA AGONIST**

Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
PROVENTIL HFA (INHALATION)	0.1%	OFF	Yes			
ALBUTEROL SYRUP (ORAL)	0.6%	ON	Yes-Generic			
ALBUTEROL NEB SOLN 2.5 MG/0.5 ML (INHALATION)	0.0%	ON	Yes-Generic			



<b>BRONCHODILATORS, BETA AGONIST</b>						
<b>Brand Name</b>	<b>Current Market Share</b>	<b>Current PDL Status</b>	<b>PDL Recommendation</b>	<b>COMMITTEE RECOMMENDATIONS</b>	<b>STATE MODIFICATIONS</b>	<b>SECRETARY MODIFICATIONS</b>
MAXAIR (INHALATION)	0.2%	ON	Yes			
ALBUTEROL TABLET (ORAL)	0.1%	ON	Yes-Generic			
ALBUTEROL NEB SOLN 100 MG/20 ML (INHALATION)	0.7%	ON	Yes-Generic			
PROAIR HFA (INHALATION)	35.2%	ON	Yes			
VENTOLIN HFA (INHALATION)	41.9%	ON	No			
ALBUTEROL NEB SOLN 2.5 MG/3 ML (INHALATION)	18.2%	ON	Yes-Generic			
XOPENEX HFA (INHALATION)	0.5%	OFF	No			
METAPROTERENOL SYRUP (ORAL)	0.0%	OFF	No-Generic			
TERBUTALINE (ORAL)	0.1%	ON	Yes-Generic			
FORADIL (INHALATION)	0.2%	ON	Yes			
ALBUTEROL NEB SOLN 0.63, 1.25 MG (INHALATION)	1.1%	OFF	No-Generic			
SEREVENT (INHALATION)	0.6%	ON	No			
ALBUTEROL ER (ORAL)	0.0%	ON	Yes-Generic			
LEVALBUTEROL NEB SOLN CONC (INHALATION)	0.0%	OFF	No-Generic			
XOPENEX NEB SOLN (INHALATION)	0.5%	OFF	No			
METAPROTERENOL TABLET (ORAL)	0.0%	OFF	No-Generic			
ARCAPTA NEOHALER (INHALATION)	0.0%	OFF	No			
PERFOROMIST (INHALATION)	0.1%	OFF	No			
BROVANA (INHALATION)	0.0%	OFF	No			

- Discussion:
- Catherine Decker stated that there is a patient safety concern when members of any age need to know how much drug they have left in their rescue inhaler. Ventolin HFA is the only product with a dose counter.
- Bradley Fedderly stated that metered dose inhalers have been around for a long time. He wondered if there is any research that demonstrates the benefit of a dose counter.
- Kevin Izard stated a dose counter seems easy to have and urged manufacturers to include them, especially for this group of drugs.
- Michael Witkovsky asked about also taking Proair off to incent the manufacturer to include a dose counter.
- Pat Towers felt having a dose counter is a good idea to have and is an especially good idea for kids.
- Ronald Diamond stated the cost issues are too significant to have Ventolin preferred.
- Rick Pope noted that Wisconsin was unique in its concern with dose counter availability. He stated that the other states in the TOP\$ pool have not been concerned with the availability of a dose counter.

Motion #1

- Pat Towers made a motion to accept staff recommendations as presented but have Ventolin HFA remain preferred.
  - Second – Catherine Decker
  - The vote was 4-6 in favor of this motion. Bradley Fedderly, Al Liegel, Steve Maike, James Boblin, Kevin Izard, and Ronald Diamond were opposed.
  - Motion fails

Motion #2

- Ronald Diamond made a motion to accept staff recommendations as presented.
  - Second – Bradley Fedderly
  - The vote was 6-4 in favor of this motion. Catherine Decker, Al Liegel, Pat Towers, and Michael Witkovsky were opposed
  - Motion passes

<b>COUGH AND COLD, NARCOTIC</b>						
<b>Brand Name</b>	<b>Current Market Share</b>	<b>Current PDL Status</b>	<b>PDL Recommendation</b>	<b>COMMITTEE RECOMMENDATIONS</b>	<b>STATE MODIFICATIONS</b>	<b>SECRETARY MODIFICATIONS</b>
GUAIFENESIN/CODEINE PHOS (ORAL)	0.1%	ON	<b>Yes-Generic</b>			
GUAIFENESIN/CODEINE SYRUP OTC (ORAL)	21.0%	ON	<b>Yes-Generic</b>			
GANI-TUSS NR OTC (ORAL)	0.0%	ON	<b>Yes</b>			
GUAIFENESIN/CODEINE SYRUP (ORAL)	12.3%	ON	<b>Yes-Generic</b>			
ROBAFEN AC (ORAL)	1.0%	ON	<b>Yes-Generic</b>			
PROMETHAZINE/CODEINE SYRUP (ORAL)	60.6%	ON	<b>Yes-Generic</b>			
TUSSIONEX (ORAL)	0.4%	OFF	<b>No</b>			
PRO-CLEAR CAPS OTC (ORAL)	0.0%	OFF	<b>No</b>			
M-CLEAR WC (ORAL)	0.0%	ON	<b>Yes</b>			
TUSNEL C (ORAL)	0.0%	OFF	<b>No-Generic</b>			
M-END PE (ORAL)	0.0%	OFF	<b>No-Generic</b>			
PRO-RED AC OTC (ORAL)	0.0%	OFF	<b>No</b>			
PRO-CLEAR AC OTC (ORAL)	0.0%	OFF	<b>No</b>			
POLY-TUSSIN DHC (ORAL)	0.0%	ON	<b>No</b>			
CAPCOF (ORAL)	0.0%	OFF	<b>No</b>			
COLDROUGH PD (ORAL)	0.0%	ON	<b>No</b>			
MYTUSSIN DAC OTC (ORAL)	0.0%	OFF	<b>No</b>			
CHERATUSSIN DAC OTC (ORAL)	0.0%	OFF	<b>No</b>			
PHENYLHISTINE DH OTC (ORAL)	0.0%	ON	<b>No</b>			
ALAHIST DHC (ORAL)	0.0%	OFF	<b>No</b>			
LORTUSS EX OTC (ORAL) (NO RESTRICTIONS)	0.0%	OFF	<b>No</b>			
ALA-HIST AC (ORAL)	0.0%	OFF	<b>No</b>			
POLY HIST NC (ORAL)	0.0%	OFF	<b>No</b>			
Z-TUSS AC OTC (ORAL)	0.0%	OFF	<b>No</b>			
POLY HIST DHC (ORAL)	0.0%	OFF	<b>No</b>			
POLY-TUSSIN EX (ORAL)	0.0%	OFF	<b>No</b>			
TUSNEL PED-C (ORAL)	0.0%	OFF	<b>No</b>			
MAR-COF CG (ORAL)	0.0%	OFF	<b>No</b>			
POLY-TUSSIN AC OTC (ORAL) (NO	0.0%	ON	<b>No</b>			

COUGH AND COLD, NARCOTIC						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
RESTRICTIONS)						
PROMETHAZINE VC/CODEINE SYRUP (ACTAVIS) (ORAL)	0.1%	ON	Yes			
MAR-COF BP (ORAL)	0.0%	OFF	No			
RYDEX OTC (ORAL)	0.0%	OFF	No			
TUSSIGON (ORAL)	0.0%	OFF	No			
PROMETHAZINE VC/CODEINE SYRUP (QUALITEST) (ORAL)	2.6%	ON	Yes			
MESEHIST WC (ORAL)	0.0%	OFF	No-Generic			
ENDACOF-DC OTC (ORAL)	0.0%	OFF	No			
NEO AC OTC (ORAL)	0.0%	OFF	No			
DONATUSS DC (ORAL)	0.0%	OFF	No			
M-END WC (ORAL)	0.0%	ON	No			
MAXIPHEN CDX (ORAL)	0.0%	OFF	No			
J-COF DHC (ORAL)	0.0%	ON	No			
J-MAX DHC (ORAL)	0.0%	OFF	No			
TL-HIST CD (ORAL)	0.0%	OFF	No			
ALLFEN CDX (ORAL)	0.0%	OFF	No			
ZODRYL AC OTC (ORAL)	0.0%	OFF	No			
ZODRYL DEC OTC (ORAL)	0.0%	OFF	No			
ZODRYL DEC OTC (ORAL)	0.0%	OFF	No			
ZODRYL DAC OTC (ORAL)	0.0%	OFF	No			
VANACOF CD (ORAL)	0.0%	OFF	No			
M-CLEAR (ORAL)	0.0%	OFF	No			
Z-TUSS E OTC (ORAL)	0.0%	NR	No			
ENDAL CD OTC (ORAL)	0.0%	OFF	No			
HYDROCODONE/HOMATROPINE SYRUP (ORAL)	0.2%	OFF	No			
NOTUSS-NX (ORAL)	0.0%	OFF	No			
NOTUSS-NXD (ORAL)	0.0%	OFF	No			
ZOTEX-C (ORAL)	0.0%	OFF	No			
ALLFEN CD (ORAL)	0.0%	OFF	No			
NASOTUSS OTC (ORAL)	0.0%	OFF	No			
REZIRA (ORAL)	0.0%	OFF	No			
ZUTRIPRO (ORAL)	0.0%	OFF	No			
COTAB A (ORAL)	0.0%	OFF	No			
HYDROCODONE/CHLORPHENIRAMINE SUSP (ORAL)	1.8%	OFF	No-Generic			
COTAB AX (ORAL)	0.0%	OFF	No			
AMBIFED CD (ORAL)	0.0%	OFF	No			

<b>COUGH AND COLD, NARCOTIC</b>						
<b>Brand Name</b>	<b>Current Market Share</b>	<b>Current PDL Status</b>	<b>PDL Recommendation</b>	<b>COMMITTEE RECOMMENDATIONS</b>	<b>STATE MODIFICATIONS</b>	<b>SECRETARY MODIFICATIONS</b>
AMBIFED-G CD (ORAL)	0.0%	OFF	No			
MAXIFED-G CD (ORAL)	0.0%	OFF	No			
MAXIFED CD (ORAL)	0.0%	OFF	No			
AMBIFED CDX (ORAL)	0.0%	OFF	No			
COTABFLU (ORAL)	0.0%	OFF	No			
AMBIFED-G CDX (ORAL)	0.0%	OFF	No			
MAXIFED-G CDX (ORAL)	0.0%	OFF	No			
MAXIFLU CD (ORAL)	0.0%	OFF	No			
MAXIPHEN CD (ORAL)	0.0%	OFF	No			
MAXIFED CDX (ORAL)	0.0%	OFF	No			
MAXIFLU CDX (ORAL)	0.0%	OFF	No			
PHENFLU CD (ORAL)	0.0%	OFF	No			
PHENFLU CDX (ORAL)	0.0%	OFF	No			
TUSSICAPS (ORAL)	0.0%	OFF	No			

- Discussion: None
- Bradley Fedderly made a motion to accept staff recommendations as presented.
  - Second – Michael Witkovsky
  - All members were in favor of this motion
  - Motion passes.

<b>EPINEPHRINE, SELF-INJECTED</b>						
<b>Brand Name</b>	<b>Current Market Share</b>	<b>Current PDL Status</b>	<b>PDL Recommendation</b>	<b>COMMITTEE RECOMMENDATIONS</b>	<b>STATE MODIFICATIONS</b>	<b>SECRETARY MODIFICATIONS</b>
TWINJECT (INTRAMUSC)	0.0%	OFF	Yes			
TWINJECT LOW STRENGTH (INTRAMUSC)	0.0%	OFF	Yes			
EPIPEN (INTRAMUSC)	68.1%	ON	Yes			
EPIPEN JR (INTRAMUSC)	31.9%	ON	Yes			

- Discussion: None
- Pat Towers made a motion to accept staff recommendations as presented.
  - Second – Kevin Izard
  - All members were in favor of this motion
  - Motion passes.

**GLUCOCORTICOID, INHALED**

Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
ASMANEX (INHALATION)	0.5%	OFF	Yes			
QVAR (INHALATION)	4.2%	ON	Yes			
FLOVENT DISKUS (INHALATION)	0.6%	ON	Yes			
FLOVENT HFA (INHALATION)	23.4%	ON	Yes			
PULMICORT FLEXHALER (INHALATION)	1.9%	ON	No			
ALVESCO (INHALATION)	0.1%	OFF	No			
DULERA (INHALATION)	0.0%	NR	Yes			
SYMBICORT (INHALATION)	7.4%	ON	Yes			
ADVAIR HFA (INHALATION)	3.9%	ON	Yes			
ADVAIR DISKUS (INHALATION)	48.9%	ON	Yes			
PULMICORT 0.25, 0.5 MG RESPULES (INHALATION)	0.4%	OFF	No			
BUDESONIDE 0.25, 0.5 MG RESPULES (INHALATION)	8.1%	OFF	No-Generic			
PULMICORT 1 MG RESPULES (INHALATION)	0.5%	OFF	No			

- Discussion: None
- Al Liegel made a motion to accept staff recommendations as presented.
  - Second – Lawrence Fleming
  - All members were in favor of this motion
  - Motion passes.

INTRANASAL RHINITIS AGENTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
NASONEX (NASAL)	3.2%	OFF	Yes			
IPRATROPIUM (NASAL)	2.0%	ON	Yes-Generic			
NASACORT AQ (NASAL)	0.6%	OFF	Yes			
ASTELIN (NASAL)	0.2%	NR	Yes			
ASTEPRO (NASAL)	0.8%	ON	Yes			
BECONASE AQ (NASAL)	0.9%	ON	Yes			
PATANASE (NASAL)	0.9%	ON	Yes			
FLUTICASONE (NASAL)	87.2%	ON	Yes-Generic			
FLUNISOLIDE (NASAL)	0.9%	ON	No-Generic			
VERAMYST	0.9%	OFF	No			

INTRANASAL RHINITIS AGENTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
(NASAL)						
OMNARIS (NASAL)	0.1%	OFF	No			
RHINOCORT AQUA (NASAL)	0.3%	OFF	No			
AZELASTINE (NASAL)	2.1%	ON	No-Generic			
TRIAMCINOLONE (NASAL)	0.0%	OFF	No-Generic			

- Discussion: None
- Kevin Izard made a motion to accept staff recommendations as presented.
  - Second – Michael Witkovsky
  - All members were in favor of this motion
  - Motion passes.

LEUKOTRIENE MODIFIERS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
SINGULAIR TABLET (ORAL)	58.4%	ON	Yes			
SINGULAIR TAB CHEW (ORAL)	39.2%	ON	Yes			
SINGULAIR GRAN PACK (ORAL)	2.3%	ON	No			
ZAFIRLUKAST (ORAL)	0.0%	ON	No-Generic			
ZYFLO CR (ORAL)	0.1%	OFF	No			

- Discussion:
- Kevin Izard asked the committee why we would take zafirlukast off PDL. He stated there is hardly any utilization and there is probably a reason those members are on it.
- Catherine Decker stated she could not think of a reason why a member would need to be on zafirlukast.
- Ron Diamond questioned if the recommendation to make it non-preferred based on financial or clinical concerns? He stated we want to use less expensive medications, unless there is a clinical advantage and that zafirlukast does not have a clinical advantage.

#### Motion #1

- Kevin Izard made a motion to accept staff recommendations as presented but leave zafirlukast as preferred.
  - Second – James Boblin
  - The vote was 1 to 9 in favor of the motion. Bradley Fedderly, Lawrence Fleming, Al Liegel, Steve Maike, Pat Towers, Michael Witkovsky, James Boblin, Catherine Decker, and Ronald Diamond were opposed.
  - Motion Fails.

#### Motion #2

- Pat Towers made a motion to accept staff recommendations as presented.
  - Second – Lawrence Fleming
  - The vote was 9 to 1 in favor of the motion. Kevin Izard was opposed.
  - Motion passes.

<b>OPHTHALMIC ANTIBIOTICS</b>						
<b>Brand Name</b>	<b>Current Market Share</b>	<b>Current PDL Status</b>	<b>PDL Recommendation</b>	<b>COMMITTEE RECOMMENDATIONS</b>	<b>STATE MODIFICATIONS</b>	<b>SECRETARY MODIFICATIONS</b>
TOBRAMYCIN (OPHTHALMIC)	7.2%	ON	<b>Yes-Generic</b>			
OFLOXACIN (OPHTHALMIC)	3.6%	ON	<b>Yes-Generic</b>			
SULFACETAMIDE (OPHTHALMIC)	6.2%	ON	<b>Yes-Generic</b>			
GENTAMICIN DROPS (OPHTHALMIC)	11.3%	ON	<b>Yes-Generic</b>			
VIGAMOX (OPHTHALMIC)	15.8%	ON	<b>Yes</b>			
TOBEX OINTMENT (OPHTHALMIC)	0.5%	ON	<b>Yes</b>			
CIPROFLOXACIN SOLUTION (OPHTHALMIC)	9.2%	ON	<b>Yes-Generic</b>			
CILOXAN OINTMENT (OPHTHALMIC)	0.0%	OFF	<b>Yes</b>			
BESIVANCE (OPHTHALMIC)	0.0%	OFF	<b>Yes</b>			
TERRAMYCIN W/POLYMYXIN (OPHTHALMIC)	0.0%	NR	<b>Yes</b>			
ZYMAR (OPHTHALMIC)	0.1%	OFF	<b>Yes</b>			
MOXEZA (OPHTHALMIC)	0.0%	NR	<b>No</b>			
POLYMYXIN/TRIMETHOPRIM (OPHTHALMIC)	27.8%	ON	<b>Yes-Generic</b>			
ERYTHROMYCIN (OPHTHALMIC)	16.5%	ON	<b>Yes-Generic</b>			
GENTAMICIN OINT. (OPHTHALMIC)	1.2%	ON	<b>Yes-Generic</b>			
NEOMYCIN-POLYMYXIN-GRAMICIDIN (OPHTHALMIC)	0.0%	OFF	<b>No-Generic</b>			
BACITRACIN/POLYMYXIN B SULFATE OINT. (OPHTHALMIC)	0.1%	OFF	<b>No-Generic</b>			
QUIXIN (OPHTHALMIC)	0.0%	OFF	<b>No</b>			
AZASITE (OPHTHALMIC)	0.2%	OFF	<b>No</b>			
ZYMAXID (OPHTHALMIC)	0.0%	OFF	<b>No</b>			
NEOMYCIN/BACITRACIN/POLYMYXIN OINT (OPHTHALMIC)	0.0%	NR	<b>No-Generic</b>			
IQUIX (OPHTHALMIC)	0.0%	OFF	<b>No</b>			
BACITRACIN (OPHTHALMIC)	0.0%	OFF	<b>No-Generic</b>			
NATACYN (OPHTHALMIC)	0.0%	OFF	<b>No</b>			
LEVOFLOXACIN (OPHTHALMIC)	0.0%	OFF	<b>No-Generic</b>			

- Discussion: None
- Lawrence Fleming made a motion to accept staff recommendations as presented.
  - Second – Steve Maiké
  - All members were in favor of this motion
  - Motion passes.

**OPHTHALMICS, ANTI-INFLAMMATORIES**

<b>Brand Name</b>	<b>Current Market Share</b>	<b>Current PDL Status</b>	<b>PDL Recommendation</b>	<b>COMMITTEE RECOMMENDATIONS</b>	<b>STATE MODIFICATIONS</b>	<b>SECRETARY MODIFICATIONS</b>
LOTEMAX DROPS (OPHTHALMIC)	10.8%	ON	Yes			
FLAREX (OPHTHALMIC)	0.2%	ON	Yes			
PRED FORTE (OPHTHALMIC)	0.4%	NR	Yes			
FLUOROMETHOLONE (OPHTHALMIC)	8.4%	ON	Yes-Generic			
FML FORTE (OPHTHALMIC)	0.5%	ON	Yes			
PRED MILD (OPHTHALMIC)	1.1%	ON	Yes			
FML S.O.P. (OPHTHALMIC)	1.1%	ON	Yes			
FLURBIPROFEN (OPHTHALMIC)	2.7%	ON	Yes-Generic			
PREDNISOLONE ACETATE (OPHTHALMIC)	55.5%	ON	Yes-Generic			
DICLOFENAC (OPHTHALMIC)	12.7%	ON	Yes-Generic			
MAXIDEX (OPHTHALMIC)	0.1%	ON	Yes			
DEXAMETHASONE (OPHTHALMIC)	1.9%	ON	Yes-Generic			
KETOROLAC LS (OPHTHALMIC)	1.3%	OFF	No-Generic			
KETOROLAC (OPHTHALMIC)	0.6%	OFF	No-Generic			
NEVANAC (OPHTHALMIC)	0.5%	OFF	No			
VEXOL (OPHTHALMIC)	0.9%	ON	No			
PREDNISOLONE SOD PHOSPHATE (OPHTHALMIC)	1.0%	NR	No-Generic			
BROMDAY (OPHTHALMIC)	0.0%	OFF	No			
BROMFENAC (OPHTHALMIC)	0.0%	OFF	No-Generic			
DUREZOL (OPHTHALMIC)	0.3%	OFF	No			
ACUVAIL (OPHTHALMIC)	0.0%	OFF	No			
LOTEMAX OINTMENT (OPHTHALMIC)	0.0%	NR	No			

- Discussion: None
- Michael Witkovsky made a motion to accept staff recommendations as presented.
  - Second – Al Liegel
  - All members were in favor of this motion
  - Motion passes.

**OPHTHALMICS FOR ALLERGIC CONJUNCTIVITIS**



Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
ALREX (OPHTHALMIC)	2.6%	ON	Yes			
CROMOLYN SODIUM (OPHTHALMIC)	4.1%	ON	Yes-Generic			
KETOTIFEN OTC (OPHTHALMIC)	14.0%	ON	Yes-Generic			
OPTIVAR (OPHTHALMIC)	0.0%	OFF	Yes			
PATADAY (OPHTHALMIC)	32.6%	ON	Yes			
ALOMIDE (OPHTHALMIC)	0.0%	OFF	No			
PATANOL (OPHTHALMIC)	45.8%	ON	No			
ALAMAST (OPHTHALMIC)	0.0%	OFF	No			
EMADINE (OPHTHALMIC)	0.1%	OFF	No			
ALOCRIAL (OPHTHALMIC)	0.1%	OFF	No			
ELESTAT (OPHTHALMIC)	0.2%	OFF	No			
LASTACAFT (OPHTHALMIC)	0.1%	OFF	No			
BEPREVE (OPHTHALMIC)	0.2%	OFF	No			
EPINASTINE (OPHTHALMIC)	0.0%	OFF	No-Generic			
AZELASTINE (OPHTHALMIC)	0.3%	OFF	No-Generic			

- Discussion: None
- Kevin Izard made a motion to accept staff recommendations as presented.
  - Second – Pat Towers
  - All members were in favor of this motion
  - Motion passes.

OPHTHALMICS, GLAUCOMA AGENTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
BETOPTIC S (OPHTHALMIC)	1.2%	ON	Yes			
AZOPT (OPHTHALMIC)	3.9%	ON	Yes			
LEVOBUNOLOL (OPHTHALMIC)	1.0%	ON	Yes-Generic			
ALPHAGAN P 0.15% (OPHTHALMIC)	0.6%	NR	Yes			
BRIMONIDINE (OPHTHALMIC)	2.2%	ON	Yes-Generic			
TRAVATAN / TRAVATAN Z 2.5 ML (OPHTHALMIC)	27.4%	ON	Yes			
BETIMOL (OPHTHALMIC)	1.2%	ON	Yes			
BETAXOLOL (OPHTHALMIC)	0.2%	ON	Yes-Generic			
CARTEOLOL (OPHTHALMIC)	0.3%	ON	Yes-Generic			
OPTIPRANOLOL (OPHTHALMIC)	0.0%	NR	Yes			
PILOCARPINE	1.1%	ON	Yes-Generic			

<b>OPHTHALMICS, GLAUCOMA AGENTS</b>						
<b>Brand Name</b>	<b>Current Market Share</b>	<b>Current PDL Status</b>	<b>PDL Recommendation</b>	<b>COMMITTEE RECOMMENDATIONS</b>	<b>STATE MODIFICATIONS</b>	<b>SECRETARY MODIFICATIONS</b>
(OPHTHALMIC)						
TRAVATAN / TRAVATAN Z 5 ML (OPHTHALMIC)	5.8%	ON	Yes			
COMBIGAN (OPHTHALMIC)	4.7%	ON	Yes			
LUMIGAN 2.5ML (OPHTHALMIC)	1.6%	OFF	No			
DORZOLAMIDE (OPHTHALMIC)	1.8%	ON	Yes-Generic			
TIMOLOL (OPHTHALMIC)	13.9%	ON	Yes-Generic			
METIPRANOLOL (OPHTHALMIC)	0.1%	ON	No-Generic			
ISTALOL (OPHTHALMIC)	0.4%	ON	No			
ALPHAGAN P 0.1% (OPHTHALMIC)	4.7%	ON	No			
DORZOLAMIDE / TIMOLOL (OPHTHALMIC)	7.0%	ON	Yes-Generic			
LATANOPROST 2.5 ML (OPHTHALMIC)	16.7%	ON	No-Generic			
LUMIGAN 5ML (OPHTHALMIC)	0.7%	OFF	No			
APRACLONIDINE (OPHTHALMIC)	0.0%	OFF	No-Generic			
BRIMONIDINE P 0.15% (OPHTHALMIC)	3.4%	ON	No-Generic			
LUMIGAN 7.5ML (OPHTHALMIC)	0.0%	OFF	No			
IOPIDINE (OPHTHALMIC)	0.0%	OFF	No			

- Discussion: None
- Bradley Fedderly made a motion to accept staff recommendations as presented.
  - Second – Ronald Diamond
  - All members were in favor of this motion
  - Motion passes.

<b>OTIC ANTIBIOTICS</b>						
<b>Brand Name</b>	<b>Current Market Share</b>	<b>Current PDL Status</b>	<b>PDL Recommendation</b>	<b>COMMITTEE RECOMMENDATIONS</b>	<b>STATE MODIFICATIONS</b>	<b>SECRETARY MODIFICATIONS</b>
OFLOXACIN (OTIC)	35.7%	ON	Yes-Generic			
CORTISPORIN-TC (OTIC)	0.0%	OFF	No			
COLY-MYCIN S (OTIC)	0.0%	ON	Yes			
NEOMYCIN/POLYMYXIN/HC SOLN/SUSP (OTIC)	37.3%	ON	Yes-Generic			
CIPRODEX (OTIC)	2.6%	OFF	Yes			
CIPRO HC (OTIC)	24.4%	ON	Yes			

<b>OTIC ANTIBIOTICS</b>						
<b>Brand Name</b>	<b>Current Market Share</b>	<b>Current PDL Status</b>	<b>PDL Recommendation</b>	<b>COMMITTEE RECOMMENDATIONS</b>	<b>STATE MODIFICATIONS</b>	<b>SECRETARY MODIFICATIONS</b>
CETRAXAL (OTIC)	0.0%	OFF	No			

- Discussion: None
- Ronald Diamond made a motion to accept staff recommendations as presented.
  - Second – Lawrence Fleming
  - All members were in favor of this motion
  - Motion passes.

<b>IMMUNOMODULATORS, ATOPIC DERMATITIS</b>						
<b>Brand Name</b>	<b>Current Market Share</b>	<b>Current PDL Status</b>	<b>PDL Recommendation</b>	<b>COMMITTEE RECOMMENDATIONS</b>	<b>STATE MODIFICATIONS</b>	<b>SECRETARY MODIFICATIONS</b>
ELIDEL (TOPICAL)	47.2%	OFF	No			
PROTOPIC (TOPICAL)	52.8%	OFF	No			

- Discussion: None
- Ronald Diamond made a motion to accept staff recommendations as presented.
  - Second – Al Liegel
  - All members were in favor of this motion
  - Motion passes.

<b>STERIODS, TOPICAL LOW</b>						
<b>Brand Name</b>	<b>Current Market Share</b>	<b>Current PDL Status</b>	<b>PDL Recommendation</b>	<b>COMMITTEE RECOMMENDATIONS</b>	<b>STATE MODIFICATIONS</b>	<b>SECRETARY MODIFICATIONS</b>
HYDROCORTISONE ACETATE CREAM OTC (TOPICAL)	0.4%	ON	Yes-Generic			
HYDROCORTISONE OINT. OTC (TOPICAL)	1.2%	ON	Yes-Generic			
HYDROCORTISONE CREAM OTC (TOPICAL)	5.9%	ON	Yes-Generic			
DESONIDE CREAM (TOPICAL)	7.4%	ON	Yes-Generic			
DESONIDE OINT. (TOPICAL)	9.3%	ON	Yes-Generic			
HYDROCORTISONE ACETATE OINT. OTC (TOPICAL)	0.0%	ON	Yes-Generic			
HYDROCORTISONE CREAM (TOPICAL)	38.9%	ON	Yes-Generic			
HYDROCORTISONE LOTION OTC (TOPICAL)	0.9%	ON	Yes-Generic			
HYDROCORTISONE OINT. (TOPICAL)	30.1%	ON	Yes-Generic			
HYDROCORTISONE LOTION (TOPICAL)	1.6%	ON	Yes-Generic			
ALCLOMETASONE DIPROPIONATE CREAM (TOPICAL)	0.0%	OFF	No-Generic			

STEROIDS, TOPICAL LOW						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
CAPEX SHAMPOO (TOPICAL)	0.7%	ON	No			
DERMA-SMOOTHIE-FS (TOPICAL)	1.0%	OFF	No			
HYDROCORTISONE / ALOE GEL (TOPICAL)	0.0%	ON	No-Generic			
NUZON (TOPICAL)	0.0%	NR	No			
DESONIDE LOTION (TOPICAL)	2.6%	ON	No-Generic			
ALCLOMETASONE DIPROPIONATE OINT. (TOPICAL)	0.0%	OFF	No-Generic			
HYDROCORTISONE ACETATE / UREA (TOPICAL)	0.0%	NR	No-Generic			
TEXACORT (TOPICAL)	0.0%	NR	No			
HYDROCORTISONE / ALOE LOTION (TOPICAL)	0.0%	ON	No-Generic			
DESONATE GEL TOPICAL)	0.0%	OFF	No-Generic			
PEDIADERM HC (TOPICAL)	0.0%	NR	No			
PEDIADERM TA (TOPICAL)	0.0%	NR	No			
VERDESO (TOPICAL)	0.0%	OFF	No			
DESONIL + PLUS (TOPICAL)	0.0%	NR	No			

- Discussion: None
- Ronald Diamond made a motion to accept staff recommendations as presented.
  - Second – Pat Towers
  - All members were in favor of this motion
  - Motion passes.

STEROIDS, TOPICAL MEDIUM						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
HYDROCORTISONE BUTYRATE SOLUTION BRAND (TOPICAL)	0.0%	OFF	No-Generic			
HYDROCORTISONE BUTYRATE OINT. BRAND (TOPICAL)	0.0%	OFF	No-Generic			
HYDROCORTISONE BUTYRATE OINT. (TOPICAL)	0.1%	OFF	No-Generic			
HYDROCORTISONE VALERATE CREAM (TOPICAL)	22.1%	ON	Yes-Generic			
CLODERM (TOPICAL)	0.1%	OFF	Yes			
HYDROCORTISONE BUTYRATE SOLUTION (TOPICAL)	0.0%	OFF	No-Generic			
FLUOCINOLONE ACETONIDE SOLUTION (TOPICAL)	6.3%	ON	Yes-Generic			
FLUTICASONE PROPIONATE OINT. (TOPICAL)	14.0%	ON	Yes-Generic			
FLUTICASONE PROPIONATE CREAM (TOPICAL)	27.0%	ON	Yes-Generic			
HYDROCORTISONE BUTYRATE CREAM BRAND (TOPICAL)	0.0%	OFF	No-Generic			
PANDEL (TOPICAL)	0.0%	OFF	No			

<b>STEROIDS, TOPICAL MEDIUM</b>						
<b>Brand Name</b>	<b>Current Market Share</b>	<b>Current PDL Status</b>	<b>PDL Recommendation</b>	<b>COMMITTEE RECOMMENDATIONS</b>	<b>STATE MODIFICATIONS</b>	<b>SECRETARY MODIFICATIONS</b>
MOMETASONE FUROATE CREAM (TOPICAL)	2.5%	OFF	No-Generic			
FLUOCINOLONE ACETONIDE OINT. (TOPICAL)	11.3%	ON	Yes-Generic			
FLUOCINOLONE ACETONIDE CREAM (TOPICAL)	6.1%	ON	Yes-Generic			
HYDROCORTISONE VALERATE OINT. (TOPICAL)	8.1%	ON	Yes-Generic			
MOMETASONE FUROATE OINT. (TOPICAL)	1.4%	OFF	No-Generic			
PREDNICARBATE CREAM (TOPICAL)	0.1%	OFF	No-Generic			
HYDROCORTISONE BUTYRATE CREAM (TOPICAL)	0.1%	OFF	No-Generic			
LUXIQ (TOPICAL)	0.4%	OFF	No			
MOMETASONE FUROATE SOLUTION (TOPICAL)	0.1%	OFF	No-Generic			
PREDNICARBATE OINT. (TOPICAL)	0.0%	OFF	No-Generic			
CORDRAN TAPE (TOPICAL)	0.2%	OFF	No			
MOMEXIN (TOPICAL)	0.0%	OFF	No			
CUTIVATE LOTION (TOPICAL)	0.1%	OFF	No			

- Discussion: None
- Bradley Fedderly made a motion to accept staff recommendations as presented.
  - Second – Al Liegel
  - All members were in favor of this motion
  - Motion passes.

<b>STEROIDS, TOPICAL HIGH</b>						
<b>Brand Name</b>	<b>Current Market Share</b>	<b>Current PDL Status</b>	<b>PDL Recommendation</b>	<b>COMMITTEE RECOMMENDATIONS</b>	<b>STATE MODIFICATIONS</b>	<b>SECRETARY MODIFICATIONS</b>
BETAMETHASONE VALERATE CREAM (TOPICAL)	1.1%	ON	Yes-Generic			
BETAMETHASONE DIPROPIONATE CREAM (TOPICAL)	3.6%	ON	Yes-Generic			
TRIAMCINOLONE ACETONIDE CREAM (TOPICAL)	49.0%	ON	Yes-Generic			
FLUOCINONIDE CREAM (TOPICAL)	2.8%	ON	Yes-Generic			
BETAMETHASONE VALERATE OINT. (TOPICAL)	1.3%	ON	Yes-Generic			
BETAMETHASONE DIPROPIONATE LOTION (TOPICAL)	0.8%	ON	Yes-Generic			
BETAMETHASONE VALERATE LOTION (TOPICAL)	0.4%	ON	Yes-Generic			
BETAMETHASONE DIPROPIONATE OINT. (TOPICAL)	2.3%	ON	Yes-Generic			
TRIAMCINOLONE ACETONIDE OINT. (TOPICAL)	27.3%	ON	Yes-Generic			
FLUOCINONIDE SOLUTION (TOPICAL)	1.5%	ON	Yes-Generic			
FLUOCINONIDE EMOLLIENT (TOPICAL)	0.3%	ON	Yes-Generic			
FLUOCINONIDE GEL (TOPICAL)	0.4%	ON	Yes-Generic			

STEROIDS, TOPICAL HIGH						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
FLUOCINONIDE OINT. (TOPICAL)	4.1%	ON	Yes-Generic			
BETAMET DIPROP / PROP GLY CREAM (TOPICAL)	1.2%	ON	No-Generic			
AMCINONIDE LOTION (TOPICAL)	0.0%	OFF	No-Generic			
DIFLORASONE DIACETATE OINT. (TOPICAL)	0.0%	OFF	No-Generic			
HALOG OINT. (TOPICAL)	0.0%	OFF	No			
TRIAMCINOLONE ACETONIDE LOTION (TOPICAL)	2.0%	ON	No-Generic			
AMCINONIDE CREAM (TOPICAL)	0.0%	OFF	No-Generic			
BETAMETHASONE DIPROPIONATE GEL (TOPICAL)	0.1%	ON	No-Generic			
BETAMET DIPROP / PROP GLY OINT. (TOPICAL)	0.9%	ON	No-Generic			
KENALOG AEROSOL (TOPICAL)	0.0%	OFF	No			
AMCINONIDE OINT. (TOPICAL)	0.0%	OFF	No-Generic			
DIFLORASONE DIACETATE CREAM (TOPICAL)	0.0%	OFF	No-Generic			
HALOG CREAM (TOPICAL)	0.0%	OFF	No			
BETAMET DIPROP / PROP GLY LOTION (TOPICAL)	0.4%	ON	No-Generic			
DESOXIMETASONE CREAM (TOPICAL)	0.2%	OFF	No-Generic			
VANOS (TOPICAL)	0.0%	OFF	No			
DESOXIMETASONE GEL (TOPICAL)	0.0%	OFF	No-Generic			
DESOXIMETASONE OINT. (TOPICAL)	0.1%	OFF	No-Generic			

- Discussion: None
- Lawrence Fleming made a motion to accept staff recommendations as presented.
  - Second – Bradley Fedderly
  - All members were in favor of this motion
  - Motion passes.

STEROIDS, TOPICAL VERY HIGH						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
CLOBETASOL PROPIONATE CREAM (TOPICAL)	26.5%	ON	Yes-Generic			
CLOBETASOL PROPIONATE SOLUTION (TOPICAL)	19.2%	ON	Yes-Generic			
CLOBETASOL PROPIONATE OINT. (TOPICAL)	38.5%	ON	Yes-Generic			
APEXICON E (TOPICAL)	0.3%	OFF	Yes			
CLOBETASOL PROPIONATE GEL (TOPICAL)	2.5%	ON	Yes-Generic			
CLOBETASOL EMOLLIENT (TOPICAL)	3.3%	ON	Yes-Generic			
HALOBETASOL PROPIONATE CREAM (TOPICAL)	1.4%	ON	Yes-Generic			

<b>STEROIDS, TOPICAL VERY HIGH</b>						
<b>Brand Name</b>	<b>Current Market Share</b>	<b>Current PDL Status</b>	<b>PDL Recommendation</b>	<b>COMMITTEE RECOMMENDATIONS</b>	<b>STATE MODIFICATIONS</b>	<b>SECRETARY MODIFICATIONS</b>
HALOBETASOL PROPIONATE OINT. (TOPICAL)	4.9%	ON	<b>Yes-Generic</b>			
CLOBEX SHAMPOO (TOPICAL)	0.4%	OFF	<b>No</b>			
HALAC (TOPICAL)	0.0%	NR	<b>No-Generic</b>			
HALONATE (TOPICAL)	0.0%	OFF	<b>No</b>			
CLOBETASOL PROPIONATE FOAM (TOPICAL)	2.3%	ON	<b>No-Generic</b>			
OLUX-E (TOPICAL)	0.1%	OFF	<b>No</b>			
CLOBEX LOTION (TOPICAL)	0.1%	OFF	<b>No</b>			
CLOBEX SPRAY (TOPICAL)	0.3%	OFF	<b>No</b>			

- Discussion: None
- Kevin Izard made a motion to accept staff recommendations as presented.
  - Second – Bradley Fedderly
  - All members were in favor of this motion
  - Motion passes.

<b>ANTIHYPERURICEMICS</b>						
<b>Brand Name</b>	<b>Current Market Share</b>	<b>Current PDL Status</b>	<b>PDL Recommendation</b>	<b>COMMITTEE RECOMMENDATIONS</b>	<b>STATE MODIFICATIONS</b>	<b>SECRETARY MODIFICATIONS</b>
ALLOPURINOL (ORAL)	88.9%	ON	<b>Yes-Generic</b>			
PROBENECID / COLCHICINE (ORAL)	1.8%	ON	<b>Yes-Generic</b>			
PROBENECID (ORAL)	1.6%	ON	<b>Yes-Generic</b>			
COLCRYS (ORAL)	4.2%	OFF	<b>No</b>			
ULORIC (ORAL)	3.5%	OFF	<b>No</b>			

- Discussion: None
- Pat Towers made a motion to accept staff recommendations as presented.
  - Second – Steve Maike
  - All members were in favor of this motion
  - Motion passes.

<b>BILE SALTS</b>						
<b>Brand Name</b>	<b>Current Market Share</b>	<b>Current PDL Status</b>	<b>PDL Recommendation</b>	<b>COMMITTEE RECOMMENDATIONS</b>	<b>STATE MODIFICATIONS</b>	<b>SECRETARY MODIFICATIONS</b>
URSODIOL CAPSULE (ORAL)	77.3%	ON	<b>Yes-Generic</b>			
URSO (ORAL)	0.7%	OFF	<b>No</b>			

<b>BILE SALTS</b>						
<b>Brand Name</b>	<b>Current Market Share</b>	<b>Current PDL Status</b>	<b>PDL Recommendation</b>	<b>COMMITTEE RECOMMENDATIONS</b>	<b>STATE MODIFICATIONS</b>	<b>SECRETARY MODIFICATIONS</b>
URSODIOL TABLET (ORAL)	21.9%	ON	<b>Yes-Generic</b>			
CHENODAL (ORAL)	0.0%	OFF	<b>No</b>			

- Discussion: None
- Ronald Diamond made a motion to accept staff recommendations as presented.
  - Second – Michael Witkovsky
  - All members were in favor of this motion
  - Motion passes.

<b>OPHTHALMIC ANTIBIOTIC-STEROID COMBINATIONS</b>						
<b>Brand Name</b>	<b>Current Market Share</b>	<b>Current PDL Status</b>	<b>PDL Recommendation</b>	<b>COMMITTEE RECOMMENDATIONS</b>	<b>STATE MODIFICATIONS</b>	<b>SECRETARY MODIFICATIONS</b>
BLEPHAMIDE (OPHTHALMIC)	1.6%	NR	<b>Yes</b>			
TOBRADEX SUSPENSION (OPHTHALMIC)	0.3%	NR	<b>Yes</b>			
BLEPHAMIDE S.O.P. (OPHTHALMIC)	1.4%	NR	<b>Yes</b>			
ZYLET (OPHTHALMIC)	3.1%	NR	<b>Yes</b>			
NEOMYCIN/POLYMYXIN/DEXAMETHASONE (OPHTHALMIC)	23.3%	NR	<b>Yes-Generic</b>			
TOBRADEX OINTMENT (OPHTHALMIC)	15.0%	NR	<b>Yes</b>			
PRED-G OINT. (OPHTHALMIC)	0.1%	NR	<b>Yes</b>			
PRED-G DROPS SUSP (OPHTHALMIC)	0.1%	NR	<b>Yes</b>			
SULFACETAMIDE / PREDNISOLONE (OPHTHALMIC)	3.0%	NR	<b>Yes-Generic</b>			
NEOMYCIN/BACITRACIN/POLY/HC (OPHTHALMIC)	0.0%	NR	<b>No-Generic</b>			
NEOMYCIN/BACITRACIN/POLY/HC (OPHTHALMIC)	0.0%	NR	<b>No-Generic</b>			
TOBRAMYCIN / DEXAMETHASONE SUSPENSION (OPHTHALMIC)	44.2%	NR	<b>No-Generic</b>			
NEOMYCIN/POLYMYXIN/HC (OPHTHALMIC)	5.7%	NR	<b>No-Generic</b>			
TOBRADEX ST (OPHTHALMIC)	2.3%	NR	<b>No</b>			

- Discussion: None
- Al Liegel made a motion to accept staff recommendations as presented.
  - Second – Ronald Diamond
  - All members were in favor of this motion
  - Motion passes.

**OTIC ANTI-INFECTIVES & ANESTHETICS**



Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
VOSOL HC (OTIC)	0.0%	NR	Yes			
ACETIC ACID/ALUMINUM (OTIC)	0.3%	NR	Yes-Generic			
ANTIPYRINE / BENZOCAINE (OTIC)	78.6%	NR	Yes-Generic			
PRAMOTIC (OTIC)	0.0%	NR	Yes			
PINNACAINE (OTIC)	0.0%	NR	Yes			
ACETIC ACID (OTIC)	2.3%	NR	Yes-Generic			
OTOZIN (OTIC)	0.0%	NR	No			
BOROFAIR (OTIC)	0.0%	NR	No			
OTIC CARE (OTIC)	0.0%	NR	No			
TRIOXIN (OTIC)	0.0%	NR	No			
MYOXIN (OTIC)	0.0%	NR	No			
ZINOTIC (OTIC)	0.0%	NR	No			
ZINOTIC ES (OTIC)	0.0%	NR	No			
NEOTIC (OTIC)	0.0%	NR	No			
PR OTIC SOLUTION (OTIC)	0.0%	NR	No			
ACETIC ACID HC (OTIC)	3.6%	NR	No-Generic			
TREAGAN OTIC (OTIC)	0.3%	NR	No			
AA/ANTPY/BCAINE/POLICO/AL ACET (OTIC)	14.8%	NR	No-Generic			

- Discussion: None
- Kevin Izard made a motion to accept staff recommendations as presented.
  - Second – Steve Maike
  - All members were in favor of this motion
  - Motion passes.

**General Discussion Note:**

Ronald Diamond requested that STAT-PA functionality be enhanced to allow one prior authorization to be valid for all strengths of a particular drug. He stated it makes no sense to have to get a new prior authorization every time you change strength.

Brett Davis stated that DHS will keep Dr. Diamond posted as to the status of making prior authorizations available at the drug level.